Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470

Background and Procedure. High-risk neuroblastoma disease features are correlated with tumor vascularity, suggesting that angiogenesis inhibitors may be a useful addition to current therapeutic strategies. We therefore examined the efficacy of TNP-470 (TAP Pharmaceuticals, Deerfield, IL) in human neuroblastoma xenograft models. Results. Tumor growth rate was markedly inhibited in mice receiving TNP-470 administered alone with a treatment to control ratio (T/C) at day 21 = 0.4 (P < .001). TNP-470 also significantly inhibited tumorigenicity when administered shortly after xenograft inoculation (T/C at day 30 = 0.1, P < .001) and when administered following cyclophosphamide (T/C at day 35 = 0.1, P < .001). Conclusions. These data show that TNP-470 is a potent inhibitor of human neuroblastoma growth both alone and when given with conventional chemotherapy, suggesting that it may be a useful adjunctive therapy for high-risk neuroblastoma patients. Med. Pediatr. Oncol. 35:673-676, 2000. (C) 2000 Wiley-Liss, Inc.